Introduction

Bacterial endotoxin control is a critical part of quality management for injectable pharmaceutical products. Reliable endotoxin testing depends on more than the analytical reagent alone. Laboratory conditions, testing consumables, water quality, method suitability, sample handling and manufacturing controls all contribute to the reliability of test results and the safety of the finished product.

This guide summarises common GMP compliance risks throughout the bacterial endotoxin testing process, from laboratory preparation and reagent management to interference testing, sample stability, OOS investigations and manufacturing controls designed to prevent endotoxin contamination.

1.1 Endotoxin Testing Environment

Endotoxin testing should be performed in a clean laboratory environment at room temperature, under appropriate environmental conditions.

1.2 Testing Consumables Control

Test tubes, pipette tips, dilution bottles and other laboratory utensils must be confirmed to be pyrogen-free and suitable for endotoxin testing, including appropriate control of endotoxin adsorption. Routine sterilisation eliminates microorganisms but does not necessarily remove endotoxins. Failure to control this risk may constitute a significant GMP deficiency.

1.3 Water Requirements

Water for Bacterial Endotoxins Test (BET Water) should meet applicable pharmacopoeial requirements and the specifications established for its intended use. An endotoxin limit of less than 0.001 EU/mL should only be applied where specified by the relevant standard or approved procedure. Purified water must not be substituted unless it has been appropriately qualified and meets all applicable BET water requirements.

2.1 LAL Reagent Acceptance

Upon receipt of each batch of Limulus Amebocyte Lysate (LAL) reagent, the required sensitivity verification or standard curve verification should be completed in accordance with the applicable method and quality procedures. The reagent must not be used until the required verification has been successfully completed. Complete usage and traceability records must be maintained.

2.2 Endotoxin Reference Standard Management

National reference standards should be used to calibrate working standards, as applicable. Access, handling and use should be controlled under documented procedures, with appropriate independent checks where required. Complete usage records must be maintained. The preparation, aliquoting, storage and freeze-thaw cycles of working standards must be strictly controlled.

2.3 Storage Requirements

LAL reagents must be stored according to the manufacturer's instructions, typically at 2–8°C and protected from light where specified. Repeated freeze-thaw cycles should be avoided because they may compromise reagent performance. Prolonged storage at room temperature is not acceptable unless explicitly permitted by the validated storage conditions.

Method suitability testing is essential for demonstrating that a sample does not interfere with the bacterial endotoxin test under the selected testing conditions.

3.1 Situations Requiring Reassessment

Interference testing or method suitability should be reassessed when relevant changes occur, including:

• Changes to the product formulation

• Changes in raw material suppliers that may affect sample characteristics

• Manufacturing process changes

• Significant changes in sample pH

• Changes in the LAL reagent manufacturer or test system

• OOS endotoxin results that warrant investigation of potential analytical interference

3.2 Positive Product Control (PPC) Recovery

For applicable compendial methods, positive product control (PPC) spike recovery is generally expected to fall within 50%–200%, subject to the applicable pharmacopoeial requirements and validated procedure.

3.3 Common Approaches to Resolving Interference

Potential approaches include sample dilution, pH adjustment, the addition of suitable metal ions where scientifically justified, and the use of appropriate buffering agents or other validated techniques. The reaction mixture pH should generally be maintained within the range of 6.0–8.0 where appropriate for the selected method and reagent system. All mitigation measures must be validated for their intended use.

4.1 Sampling Equipment Requirements

For sterile injectable products, the entire sampling process must use suitable sterile, pyrogen-free and non-endotoxin-adsorbing equipment. Sampling equipment must undergo appropriate preparation or validated depyrogenation treatment before use, as applicable.

4.2 Sample Testing Time Limits

Samples must be tested within the established and validated holding time after collection. Samples exceeding the permitted holding time must be assessed according to approved procedures and must not be used for product release unless their continued suitability has been scientifically justified and authorised. Microbial proliferation during storage may increase endotoxin levels, particularly when Gram-negative bacteria are present.

5.1 Result Interpretation

For the gel-clot method, the test is valid only when the required negative controls, positive controls and positive product controls meet their acceptance criteria. If all test tubes containing the sample remain negative for gel formation, the sample may be considered compliant with the applicable endotoxin limit, provided all other method acceptance criteria are satisfied.

If any test tube produces a positive gel-clot result, the result must be interpreted according to the validated method and applicable pharmacopoeial requirements. Any OOS result must trigger a documented investigation. Retesting without a scientifically justified basis is prohibited.

5.2 Terminal Sterilisation and Endotoxin Control

Terminal sterilisation does not reliably eliminate bacterial endotoxins. Endotoxins generated by high microbial loads in intermediates may remain even after terminal sterilisation. Excessive bioburden detected during in-process controls must therefore be investigated, with root causes identified and corrective and preventive actions (CAPA) implemented.

6.1 Water for Injection (WFI) Systems

The endotoxin limit for Water for Injection (WFI) is generally 0.25 EU/mL under applicable pharmacopoeial requirements. Sampling locations, testing frequencies and alert/action limits should be established through a risk-based, validated water system monitoring programme. Daily testing at points of use may be adopted where justified by system risks and monitoring requirements.

6.2 Sterilising-Grade Filter Control

Filters must be prepared and used according to validated procedures and manufacturer instructions. Where applicable, preparation may include alkaline treatment, rinsing and sterilisation. Filter integrity must be verified at the required stages, including before use where required and after use for sterilising-grade filtration. Damaged or compromised filters may permit microbial contamination and compromise product quality.

6.3 Rubber Stoppers and Aluminium Seals

Primary packaging components must undergo appropriate cleaning and, where necessary, validated depyrogenation processes. For dry-heat depyrogenation, a process such as 250°C for 30 minutes requires complete validation demonstrating that the specified conditions consistently achieve the required endotoxin reduction without compromising component quality.

6.4 In-Process Bioburden Control of Drug Solutions

Raw materials with appropriately low endotoxin levels should be selected wherever feasible. Following compounding, the solution should undergo the required filtration process, and bioburden should be monitored according to established procedures. Gram-negative bacterial contamination must be strictly controlled to minimise endotoxin generation at the source.

This article is intended for general technical information and training purposes. Specific endotoxin limits, acceptance criteria, testing procedures and GMP requirements must be verified against the applicable pharmacopoeia, approved product specifications, validated procedures and current regulatory requirements.